Pharmacokinetics and Metabolism of the Anti-Inflammatory Agent Voltaren

Diclofenac sodium, the active substance of Voltaren®, is totally absorbed following both oral and rectal administration and is excreted, mainly in metabolised form, partly in the urine and partly in the bile. The extent of its biliary excretion varies from species to species. In the rat and the dog,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scandinavian journal of rheumatology 1978, Vol.7 (S22), p.17-29
Hauptverfasser: Riess, W., Stierlin, H., Degen, P., Faigle, J. W., Gerardin, A., Moppert, J., Sallmann, A., Schmid, K., Schweizer, A., Sulc, M., Theobald, W., Wagner, J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 29
container_issue S22
container_start_page 17
container_title Scandinavian journal of rheumatology
container_volume 7
creator Riess, W.
Stierlin, H.
Degen, P.
Faigle, J. W.
Gerardin, A.
Moppert, J.
Sallmann, A.
Schmid, K.
Schweizer, A.
Sulc, M.
Theobald, W.
Wagner, J.
description Diclofenac sodium, the active substance of Voltaren®, is totally absorbed following both oral and rectal administration and is excreted, mainly in metabolised form, partly in the urine and partly in the bile. The extent of its biliary excretion varies from species to species. In the rat and the dog, diclofenac sodium is subject to enterohepatic circulation. In man, mainly hydroxylated metabolites are produced, which are excreted in the urine in the form of glucuronides accounting for roughly 60 % of the dose administered. Oral doses of 25 mg and 50 mg, given as enteric-coated tablets, lead to mean maximum plasma concentrations of approximately 0.5 μg/ml and 1.0 μg/ml, respectively, after about two hours. Four hours after administration of these doses, the levels still detectable in the plasma are equivalent to some 10 % of the maximum concentrations. Repeated oral doses ensure uniform bio-availability of the active substance. When diclofenac sodium is administered in therapeutic doses, 99.7 % of the concentration attained in the serum is bound to protein. Diclofenac sodium does not interfere with the protein binding of other drugs, such as tolbutamide, salicylates, warfarin, aceno-coumarol, or prednisolone, but the protein binding of diclofenac sodium itself can be significantly impaired by high doses of anionic drugs, such as salicylic acid. In the rat, simultaneous administration of diclofenac sodium (1 mg/kg i.v.) and salicylic acid in a dosage ratio of 1:20 leads to increased biliary excretion of diclofenac sodium but not to any significant change in its distribution in the various organs; the latter is influenced, however, by even higher doses of salicylic acid. In man, a relative decrease in the diclofenac sodium concentrations in the plasma is observed when 1000 mg acetylsalicylic acid is given concomitantly with 50 mg Voltaren: in relation to the values recorded in response to administration of 50 mg Voltaren alone, the maximum concentrations are reduced by 37 ®17% and the areas under the concentration curves by 33 ®14% [i® s(x),N=6].
doi_str_mv 10.3109/03009747809097212
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_crossref_primary_10_3109_03009747809097212</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>74117754</sourcerecordid><originalsourceid>FETCH-LOGICAL-c533t-6aba349bac29a820f51de966c6e4855f2a72bd3cf90627a7f492281f1115f2cf3</originalsourceid><addsrcrecordid>eNp9kEtLxDAUhYMoOj5-gLjpyl01j7Zp0M0w-IIRXajbcpsmTjVNNMkg8-_NOIMgoqu7-M45XD6EDgk-YQSLU8wwFrzgNRbpUkI30IiUmOacM7qJRkuepwDdQbshvGCMC8HFNtoSdc2KEbq6n4EfQLrX3qrYy5CB7bJbFaF1pg9D5nQWZyob29jnN1YbGAaIzi-y8bOyMXtyJoJXdh9taTBBHazvHnq8vHiYXOfTu6ubyXiay5KxmFfQAitEC5IKqCnWJemUqCpZqaIuS02B07ZjUgtcUQ5cF4LSmmhCSIJSsz10vNp98-59rkJshj5IZQxY5eah4QUhnJdFCpJVUHoXgle6efP9AH7RENws1TW_1KXO0Xp83g6q-258uUr0fEV7q11y9uG86ZoIC-O89mBlH5bDf4-f_ajPFJg4k0le8-Lm3iZr_7z2CS4Fjf4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>74117754</pqid></control><display><type>article</type><title>Pharmacokinetics and Metabolism of the Anti-Inflammatory Agent Voltaren</title><source>MEDLINE</source><source>Taylor &amp; Francis Medical Library - CRKN</source><source>Taylor &amp; Francis Journals Complete</source><creator>Riess, W. ; Stierlin, H. ; Degen, P. ; Faigle, J. W. ; Gerardin, A. ; Moppert, J. ; Sallmann, A. ; Schmid, K. ; Schweizer, A. ; Sulc, M. ; Theobald, W. ; Wagner, J.</creator><creatorcontrib>Riess, W. ; Stierlin, H. ; Degen, P. ; Faigle, J. W. ; Gerardin, A. ; Moppert, J. ; Sallmann, A. ; Schmid, K. ; Schweizer, A. ; Sulc, M. ; Theobald, W. ; Wagner, J.</creatorcontrib><description>Diclofenac sodium, the active substance of Voltaren®, is totally absorbed following both oral and rectal administration and is excreted, mainly in metabolised form, partly in the urine and partly in the bile. The extent of its biliary excretion varies from species to species. In the rat and the dog, diclofenac sodium is subject to enterohepatic circulation. In man, mainly hydroxylated metabolites are produced, which are excreted in the urine in the form of glucuronides accounting for roughly 60 % of the dose administered. Oral doses of 25 mg and 50 mg, given as enteric-coated tablets, lead to mean maximum plasma concentrations of approximately 0.5 μg/ml and 1.0 μg/ml, respectively, after about two hours. Four hours after administration of these doses, the levels still detectable in the plasma are equivalent to some 10 % of the maximum concentrations. Repeated oral doses ensure uniform bio-availability of the active substance. When diclofenac sodium is administered in therapeutic doses, 99.7 % of the concentration attained in the serum is bound to protein. Diclofenac sodium does not interfere with the protein binding of other drugs, such as tolbutamide, salicylates, warfarin, aceno-coumarol, or prednisolone, but the protein binding of diclofenac sodium itself can be significantly impaired by high doses of anionic drugs, such as salicylic acid. In the rat, simultaneous administration of diclofenac sodium (1 mg/kg i.v.) and salicylic acid in a dosage ratio of 1:20 leads to increased biliary excretion of diclofenac sodium but not to any significant change in its distribution in the various organs; the latter is influenced, however, by even higher doses of salicylic acid. In man, a relative decrease in the diclofenac sodium concentrations in the plasma is observed when 1000 mg acetylsalicylic acid is given concomitantly with 50 mg Voltaren: in relation to the values recorded in response to administration of 50 mg Voltaren alone, the maximum concentrations are reduced by 37 ®17% and the areas under the concentration curves by 33 ®14% [i® s(x),N=6].</description><identifier>ISSN: 0300-9742</identifier><identifier>ISSN: 0301-3847</identifier><identifier>EISSN: 1502-7732</identifier><identifier>DOI: 10.3109/03009747809097212</identifier><identifier>PMID: 98834</identifier><language>eng</language><publisher>Norway: Informa UK Ltd</publisher><subject>Administration, Oral ; Animals ; Biological Availability ; Blood Proteins - metabolism ; Chemical Phenomena ; Chemistry ; Diclofenac - administration &amp; dosage ; Diclofenac - metabolism ; Dogs ; Haplorhini ; Humans ; Phenylacetates - metabolism ; Protein Binding ; Rats ; Rectum ; Salicylates - pharmacology ; Species Specificity ; Tissue Distribution</subject><ispartof>Scandinavian journal of rheumatology, 1978, Vol.7 (S22), p.17-29</ispartof><rights>1978 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1978</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c533t-6aba349bac29a820f51de966c6e4855f2a72bd3cf90627a7f492281f1115f2cf3</citedby><cites>FETCH-LOGICAL-c533t-6aba349bac29a820f51de966c6e4855f2a72bd3cf90627a7f492281f1115f2cf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/03009747809097212$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/03009747809097212$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,776,780,4009,27902,27903,27904,59623,59729,60412,60518,61197,61232,61378,61413</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/98834$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Riess, W.</creatorcontrib><creatorcontrib>Stierlin, H.</creatorcontrib><creatorcontrib>Degen, P.</creatorcontrib><creatorcontrib>Faigle, J. W.</creatorcontrib><creatorcontrib>Gerardin, A.</creatorcontrib><creatorcontrib>Moppert, J.</creatorcontrib><creatorcontrib>Sallmann, A.</creatorcontrib><creatorcontrib>Schmid, K.</creatorcontrib><creatorcontrib>Schweizer, A.</creatorcontrib><creatorcontrib>Sulc, M.</creatorcontrib><creatorcontrib>Theobald, W.</creatorcontrib><creatorcontrib>Wagner, J.</creatorcontrib><title>Pharmacokinetics and Metabolism of the Anti-Inflammatory Agent Voltaren</title><title>Scandinavian journal of rheumatology</title><addtitle>Scand J Rheumatol Suppl</addtitle><description>Diclofenac sodium, the active substance of Voltaren®, is totally absorbed following both oral and rectal administration and is excreted, mainly in metabolised form, partly in the urine and partly in the bile. The extent of its biliary excretion varies from species to species. In the rat and the dog, diclofenac sodium is subject to enterohepatic circulation. In man, mainly hydroxylated metabolites are produced, which are excreted in the urine in the form of glucuronides accounting for roughly 60 % of the dose administered. Oral doses of 25 mg and 50 mg, given as enteric-coated tablets, lead to mean maximum plasma concentrations of approximately 0.5 μg/ml and 1.0 μg/ml, respectively, after about two hours. Four hours after administration of these doses, the levels still detectable in the plasma are equivalent to some 10 % of the maximum concentrations. Repeated oral doses ensure uniform bio-availability of the active substance. When diclofenac sodium is administered in therapeutic doses, 99.7 % of the concentration attained in the serum is bound to protein. Diclofenac sodium does not interfere with the protein binding of other drugs, such as tolbutamide, salicylates, warfarin, aceno-coumarol, or prednisolone, but the protein binding of diclofenac sodium itself can be significantly impaired by high doses of anionic drugs, such as salicylic acid. In the rat, simultaneous administration of diclofenac sodium (1 mg/kg i.v.) and salicylic acid in a dosage ratio of 1:20 leads to increased biliary excretion of diclofenac sodium but not to any significant change in its distribution in the various organs; the latter is influenced, however, by even higher doses of salicylic acid. In man, a relative decrease in the diclofenac sodium concentrations in the plasma is observed when 1000 mg acetylsalicylic acid is given concomitantly with 50 mg Voltaren: in relation to the values recorded in response to administration of 50 mg Voltaren alone, the maximum concentrations are reduced by 37 ®17% and the areas under the concentration curves by 33 ®14% [i® s(x),N=6].</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Biological Availability</subject><subject>Blood Proteins - metabolism</subject><subject>Chemical Phenomena</subject><subject>Chemistry</subject><subject>Diclofenac - administration &amp; dosage</subject><subject>Diclofenac - metabolism</subject><subject>Dogs</subject><subject>Haplorhini</subject><subject>Humans</subject><subject>Phenylacetates - metabolism</subject><subject>Protein Binding</subject><subject>Rats</subject><subject>Rectum</subject><subject>Salicylates - pharmacology</subject><subject>Species Specificity</subject><subject>Tissue Distribution</subject><issn>0300-9742</issn><issn>0301-3847</issn><issn>1502-7732</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1978</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLxDAUhYMoOj5-gLjpyl01j7Zp0M0w-IIRXajbcpsmTjVNNMkg8-_NOIMgoqu7-M45XD6EDgk-YQSLU8wwFrzgNRbpUkI30IiUmOacM7qJRkuepwDdQbshvGCMC8HFNtoSdc2KEbq6n4EfQLrX3qrYy5CB7bJbFaF1pg9D5nQWZyob29jnN1YbGAaIzi-y8bOyMXtyJoJXdh9taTBBHazvHnq8vHiYXOfTu6ubyXiay5KxmFfQAitEC5IKqCnWJemUqCpZqaIuS02B07ZjUgtcUQ5cF4LSmmhCSIJSsz10vNp98-59rkJshj5IZQxY5eah4QUhnJdFCpJVUHoXgle6efP9AH7RENws1TW_1KXO0Xp83g6q-258uUr0fEV7q11y9uG86ZoIC-O89mBlH5bDf4-f_ajPFJg4k0le8-Lm3iZr_7z2CS4Fjf4</recordid><startdate>1978</startdate><enddate>1978</enddate><creator>Riess, W.</creator><creator>Stierlin, H.</creator><creator>Degen, P.</creator><creator>Faigle, J. W.</creator><creator>Gerardin, A.</creator><creator>Moppert, J.</creator><creator>Sallmann, A.</creator><creator>Schmid, K.</creator><creator>Schweizer, A.</creator><creator>Sulc, M.</creator><creator>Theobald, W.</creator><creator>Wagner, J.</creator><general>Informa UK Ltd</general><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1978</creationdate><title>Pharmacokinetics and Metabolism of the Anti-Inflammatory Agent Voltaren</title><author>Riess, W. ; Stierlin, H. ; Degen, P. ; Faigle, J. W. ; Gerardin, A. ; Moppert, J. ; Sallmann, A. ; Schmid, K. ; Schweizer, A. ; Sulc, M. ; Theobald, W. ; Wagner, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c533t-6aba349bac29a820f51de966c6e4855f2a72bd3cf90627a7f492281f1115f2cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1978</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Biological Availability</topic><topic>Blood Proteins - metabolism</topic><topic>Chemical Phenomena</topic><topic>Chemistry</topic><topic>Diclofenac - administration &amp; dosage</topic><topic>Diclofenac - metabolism</topic><topic>Dogs</topic><topic>Haplorhini</topic><topic>Humans</topic><topic>Phenylacetates - metabolism</topic><topic>Protein Binding</topic><topic>Rats</topic><topic>Rectum</topic><topic>Salicylates - pharmacology</topic><topic>Species Specificity</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Riess, W.</creatorcontrib><creatorcontrib>Stierlin, H.</creatorcontrib><creatorcontrib>Degen, P.</creatorcontrib><creatorcontrib>Faigle, J. W.</creatorcontrib><creatorcontrib>Gerardin, A.</creatorcontrib><creatorcontrib>Moppert, J.</creatorcontrib><creatorcontrib>Sallmann, A.</creatorcontrib><creatorcontrib>Schmid, K.</creatorcontrib><creatorcontrib>Schweizer, A.</creatorcontrib><creatorcontrib>Sulc, M.</creatorcontrib><creatorcontrib>Theobald, W.</creatorcontrib><creatorcontrib>Wagner, J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Scandinavian journal of rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Riess, W.</au><au>Stierlin, H.</au><au>Degen, P.</au><au>Faigle, J. W.</au><au>Gerardin, A.</au><au>Moppert, J.</au><au>Sallmann, A.</au><au>Schmid, K.</au><au>Schweizer, A.</au><au>Sulc, M.</au><au>Theobald, W.</au><au>Wagner, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetics and Metabolism of the Anti-Inflammatory Agent Voltaren</atitle><jtitle>Scandinavian journal of rheumatology</jtitle><addtitle>Scand J Rheumatol Suppl</addtitle><date>1978</date><risdate>1978</risdate><volume>7</volume><issue>S22</issue><spage>17</spage><epage>29</epage><pages>17-29</pages><issn>0300-9742</issn><issn>0301-3847</issn><eissn>1502-7732</eissn><abstract>Diclofenac sodium, the active substance of Voltaren®, is totally absorbed following both oral and rectal administration and is excreted, mainly in metabolised form, partly in the urine and partly in the bile. The extent of its biliary excretion varies from species to species. In the rat and the dog, diclofenac sodium is subject to enterohepatic circulation. In man, mainly hydroxylated metabolites are produced, which are excreted in the urine in the form of glucuronides accounting for roughly 60 % of the dose administered. Oral doses of 25 mg and 50 mg, given as enteric-coated tablets, lead to mean maximum plasma concentrations of approximately 0.5 μg/ml and 1.0 μg/ml, respectively, after about two hours. Four hours after administration of these doses, the levels still detectable in the plasma are equivalent to some 10 % of the maximum concentrations. Repeated oral doses ensure uniform bio-availability of the active substance. When diclofenac sodium is administered in therapeutic doses, 99.7 % of the concentration attained in the serum is bound to protein. Diclofenac sodium does not interfere with the protein binding of other drugs, such as tolbutamide, salicylates, warfarin, aceno-coumarol, or prednisolone, but the protein binding of diclofenac sodium itself can be significantly impaired by high doses of anionic drugs, such as salicylic acid. In the rat, simultaneous administration of diclofenac sodium (1 mg/kg i.v.) and salicylic acid in a dosage ratio of 1:20 leads to increased biliary excretion of diclofenac sodium but not to any significant change in its distribution in the various organs; the latter is influenced, however, by even higher doses of salicylic acid. In man, a relative decrease in the diclofenac sodium concentrations in the plasma is observed when 1000 mg acetylsalicylic acid is given concomitantly with 50 mg Voltaren: in relation to the values recorded in response to administration of 50 mg Voltaren alone, the maximum concentrations are reduced by 37 ®17% and the areas under the concentration curves by 33 ®14% [i® s(x),N=6].</abstract><cop>Norway</cop><pub>Informa UK Ltd</pub><pmid>98834</pmid><doi>10.3109/03009747809097212</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0300-9742
ispartof Scandinavian journal of rheumatology, 1978, Vol.7 (S22), p.17-29
issn 0300-9742
0301-3847
1502-7732
language eng
recordid cdi_crossref_primary_10_3109_03009747809097212
source MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete
subjects Administration, Oral
Animals
Biological Availability
Blood Proteins - metabolism
Chemical Phenomena
Chemistry
Diclofenac - administration & dosage
Diclofenac - metabolism
Dogs
Haplorhini
Humans
Phenylacetates - metabolism
Protein Binding
Rats
Rectum
Salicylates - pharmacology
Species Specificity
Tissue Distribution
title Pharmacokinetics and Metabolism of the Anti-Inflammatory Agent Voltaren
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T02%3A25%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetics%20and%20Metabolism%20of%20the%20Anti-Inflammatory%20Agent%20Voltaren&rft.jtitle=Scandinavian%20journal%20of%20rheumatology&rft.au=Riess,%20W.&rft.date=1978&rft.volume=7&rft.issue=S22&rft.spage=17&rft.epage=29&rft.pages=17-29&rft.issn=0300-9742&rft.eissn=1502-7732&rft_id=info:doi/10.3109/03009747809097212&rft_dat=%3Cproquest_pubme%3E74117754%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=74117754&rft_id=info:pmid/98834&rfr_iscdi=true